The GLP-1 shelf, fully verified.
Three molecules sit at the front of body-weight research today: semaglutide (single agonist), tirzepatide (GLP-1/GIP), and retatrutide (GLP-1/GIP/glucagon triple). Same purity bar across all three, same overnight shipping, same per-lot COA — so the only variable in your protocol is the molecule itself.
Retatrutide 10 mg
Triple agonist hitting GLP-1, GIP, and glucagon. The largest effect sizes seen in this class to date.
Tirzepatide 10 mg
Dual GLP-1/GIP agonist. The current research workhorse, with the deepest head-to-head dataset.
Semaglutide 5 mg
Single GLP-1 agonist. Longest human data record in the lane and the most predictable titration curve.
One receptor family, three different conversations.
If you're new to the lane, the temptation is to ask "which GLP-1 is best." That isn't quite the right question. The better one is: how many incretin receptors do you want your protocol to recruit?
Semaglutide engages a single receptor (GLP-1) and has the longest, deepest body of human data. Tirzepatide adds GIP, with newer head-to-head trials showing meaningfully larger weight reductions. Retatrutide adds glucagon — the third agonist driving energy expenditure as well as appetite — and is producing the largest effect sizes seen in this class so far, in still-emerging Phase II data.
Each step up adds receptor coverage and adds research overhead. More receptors means more sensitivity, more careful titration, more attention to the GI taper. None of these molecules is a beginner protocol; all three should be approached with a structured dose-escalation plan and clean lot data, which is what this page exists to provide.
Below: the three compounds, the stacks patients run alongside, and a decision tree if you're not sure where to start. Every card links to a PDP with the full COA archive for that molecule.
Three questions, one starting molecule.
Is this your first GLP-1 protocol?
Start with the deepest human evidence base and the gentlest titration ramp. Sema's 7-day half-life makes weekly dosing forgiving, and the GI side-effect curve is the best-characterized in the class.
Pick → Semaglutide
Plateaued on a single agonist?
Adding GIP recruits a second incretin receptor and tends to break through plateaus that pure GLP-1 protocols stall against. Most patients step up here before going higher-complexity.
Pick → Tirzepatide
Studying max effect size?
Glucagon agonism adds energy expenditure on top of appetite suppression. Triple-agonism produces the largest reductions seen — but expects a slower, more careful taper and more attentive lot tracking.
Pick → Retatrutide
Stacks patients run alongside.
All 9 stacks →
Patient questions, answered.
Six things we get asked most about the GLP-1 lane. For dosing math, use the calculator. For purity records, every PDP has the full COA archive.
Can I switch between sema, tirz, and reta?
Patients in the literature do, but the half-life differences mean you need a washout calculation. Sema and tirz are roughly comparable (~5-7 d). Element MD is similar but its triple-agonism means receptor adaptation differs. We don't make clinical recommendations — see your study lead.
Do you sell oral semaglutide?
Not at this time. The oral formulation requires SNAC absorption enhancers and produces dramatically different bioavailability profiles than the subcutaneous research literature is built on. We supply the lyophilized form used in nearly all published research.
What's the COA cadence on this lane?
Every lot, no exceptions. ISO-17025 third-party HPLC + mass spec, plus endotoxin, plus residual solvents. Each PDP shows the lot number you'll receive and links to the matching COA.
How do you ship temperature-sensitive material?
Lyophilized GLP-1 peptides ship room-temp safely for ≤72h, which we exceed comfortably with USA overnight. NAD+ and reta ship with cold packs. Reconstituted material is the researcher's responsibility — refrigerate, don't freeze, use within window per literature.
Why is reta priced highest?
Synthesis complexity. Triple-agonism means a longer modified backbone with more protecting-group chemistry, more purification steps, and lower per-batch yield. The price reflects the synthesis, not the markup.
Can I run two GLP-1s simultaneously?
No published research supports concurrent dual-GLP-1 administration, and the receptor competition makes it unlikely to add benefit. Sequence them — full taper down on one, washout, titrate up on the next.
Not sure which molecule to start with?
Take the 3-question goal quiz and we'll match you against your endpoint, your prior protocol history, and your tolerance for titration overhead.